Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Rademikibart /CBP-201 in Acute Exacerbations in COPD. The expected timing is based on the latest available company guidance and may change.
Seabreeze STAT COPD Study. 5/14/25- Ph2 Seabreeze STAT COPD initiated. 6/13/25- Supporting data presented at EAACI'25. 9/29/25- Supporting data presented at ERS'25. Topline data in H1 2026. 11/12/25:- Phase 2 Seabreeze STAT COPD enrollment ongoing; topline adjunct data expected in H1 2026. 01/12/26:- New MOA data; Seabreeze STAT COPD recruitment ongoing; topline adjunct data now expected in Mid-2026. 03/31/26:- Seabreeze STAT COPD Ph2 recruitment ongoing; topline adjunct data expected mid-2026. 04/23/26:- DMC interim efficacy review completed; no sample size change. Seabreeze STAT COPD topline data still expected Mid-2026. 05/12/26:- DMC review supports Seabreeze STAT COPD; enrollment ongoing; topline adjunct data expected mid-2026; plan post-topline FDA meeting. 06/17/26:- Seabreeze STAT COPD enrollment expected complete June 2026; topline data expected soon after Early September 2026; FDA meeting later 2026. 08/12/26:- Seabreeze STAT COPD enrollment completed. Topline data will be reported in September 2026. FDA meeting will follow topline results.
Verification
Confirm timing and program details against the company announcement or filing.